Lung Cancer
Volume 69, Issue 2 , Pages 239-244, August 2010

Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma

  • Wang Rui

      Affiliations

    • Wang Rui and Zhang You-Wei contributed equally to this study, should be regarded as joint first authors.
    • ,
  • Zhang You-Wei

      Affiliations

    • Wang Rui and Zhang You-Wei contributed equally to this study, should be regarded as joint first authors.
    • ,
  • Chen Long-Bang

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +86 25 80860153; fax: +86 25 80860153.

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China

Received 3 July 2009; received in revised form 5 October 2009; accepted 9 October 2009. published online 13 November 2009.

Abstract 

FBLN-3 has been identified as an antagonist of angiogenesis which modulates cell morphology, growth, adhesion, and motility. In the present study, we investigated the promoter methylation status of FBLN-3 gene in non-small cell lung carcinoma (NSCLC) by methylation-specific PCR and analyzed its correlation with clinicopathological factors. The methylation of FBLN-3 gene promoter was detected in 28 of 65 (43.1%) NSCLC tissue samples and 6 of 65 (9.2%) corresponding non-tumor tissue samples (P<0.05). The methylation of FBLN-3 gene promoter led to the loss of FBLN-3 gene expression in NSCLC. Additionally, FBLN-3 promoter methylation was observed to be correlated with relative poor differentiation, advanced pathological stage and lymph node metastasis of NSCLC patients (P=0.017, 0.0057 or 0.002, respectively), but not with gender, age, histological type, and smoking condition (P>0.05). These results indicated that the loss of FBLN-3 gene induced by promoter methylation might play important roles in the progression of NSCLC and FBLN-3 promoter methylation might be a promising biomarker for early detection of NSCLC.

Keywords: FBLN-3, Methylation-specific PCR, Promoter methylation, Non-small cell lung carcinoma, Immunohistochemical stainning, Biomarker

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(09)00537-6

doi:10.1016/j.lungcan.2009.10.009

Lung Cancer
Volume 69, Issue 2 , Pages 239-244, August 2010

Article Tools

* Image Usage & Resolution